A Meta-Analysis and Meta-Regression of the Efficacy, Toxicity, and Quality of Life Outcomes Following Prostate-Specific Membrane Antigen Radioligand Therapy Utilising Lutetium-177 and Actinium-225 in Metastatic Prostate Cancer,European Urology

当前位置： X-MOL 学术 › Eur. Urol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

A Meta-Analysis and Meta-Regression of the Efficacy, Toxicity, and Quality of Life Outcomes Following Prostate-Specific Membrane Antigen Radioligand Therapy Utilising Lutetium-177 and Actinium-225 in Metastatic Prostate Cancer
European Urology ( IF 25.3 ) Pub Date : 2024-09-25 , DOI: 10.1016/j.eururo.2024.09.020
Yang-Hong Dai, Po-Huang Chen, Ding-Jie Lee, Gerard Andrade, Katherine A. Vallis

Management of metastatic prostate cancer (mPCa) presents significant challenges. In this systematic review, meta-analysis, and meta-regression, the efficacy, safety, and quality of life (QoL) outcomes of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (PRLT) utilising lutetium-177 ([177Lu]Lu-PSMA) and actinium-225 ([225Ac]Ac-PSMA) were assessed.

中文翻译：

转移性前列腺癌使用镥 177 和锕 225 进行前列腺特异性膜抗原放射配体治疗后疗效、毒性和生活质量结果的荟萃分析和荟萃回归

转移性前列腺癌（mPCa）的管理面临重大挑战。在本系统评价、荟萃分析和荟萃回归中，评估了使用镥 177 （[177Lu]Lu-PSMA）和锕 225 （[225Ac]Ac-PSMA）的前列腺特异性膜抗原（PSMA）靶向放射配体疗法（PRLT）的疗效、安全性和生活质量（QoL）结果。

更新日期：2024-09-25

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南